A source-linked view of every Maridebart cafraglutide study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.
Largest indexed study
12,800 participants · NCT07037433 →Developer / research origin
Amgen
Evidence summary
Maridebart cafraglutide appears in 27 indexed studies: 6 recruiting, 12 completed and 2 with registry results posted. The highest registered development stage in this snapshot is Phase 3. These counts measure registry activity; they do not establish that Maridebart cafraglutide is safe or effective.
Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.
Current studies
Completed studies
Stopped studies
Amgen · Atherosclerotic Cardiovascular Disease · Overweight
Phase 3
Recruiting
12,800
2026-07
Amgen · Obesity or Overweight
Phase 3
Recruiting
300
2026-07
Amgen · Overweight · Obesity
Phase 1
Active, not recruiting
49
2026-07
Amgen · Obesity · Overweight
Phase 3
Not yet recruiting
950
2026-07
Amgen · Obesity · Overweight
Phase 3
Not yet recruiting
3,200
2026-07
Amgen · Heart Failure With Preserved Ejection Fraction · Heart Failure With Mildly Reduced Ejection Fraction
Phase 3
Recruiting
5,056
2026-07
Amgen · Overweight and Obesity
Phase 1
Completed
154
2026-07
Amgen · Overweight and Obesity
Phase 1
Completed
349
2026-07
Amgen · Overweight · Obesity
Phase 1
Completed
348
2026-06
Amgen · Hepatic Impairment
Phase 1
Completed
36
2026-03
Amgen · Overweight or Obesity
Phase 1
Completed
57
2026-02
Amgen · Overweight and Obesity
Phase 1
Completed
44
2026-02
Full study index
Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.
27 matching studies
Last registry update first
Latest publications
Related pages
Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.